The University of Chicago Header Logo

Connection

Mark J. Ratain to Risk Factors

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Risk Factors.
Mark J. Ratain
Connection Strength
0.233
Risk Factors
  1. The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther. 2016 Apr; 99(4):401-4.
    View in: PubMed
    Score: 0.063
  2. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance). Pharmacogenomics J. 2024 Mar 04; 24(2):6.
    View in: PubMed
    Score: 0.028
  3. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
    View in: PubMed
    Score: 0.023
  4. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634.
    View in: PubMed
    Score: 0.022
  5. Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376.
    View in: PubMed
    Score: 0.021
  6. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
    View in: PubMed
    Score: 0.020
  7. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016 04; 99(4):363-9.
    View in: PubMed
    Score: 0.016
  8. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
    View in: PubMed
    Score: 0.015
  9. Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics. 2009 Jul; 10(7):1139-46.
    View in: PubMed
    Score: 0.010
  10. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 01; 27(16):2604-14.
    View in: PubMed
    Score: 0.010
  11. Pushing the envelope: informed consent in phase I trials. Ann Oncol. 1995 Apr; 6(4):321-3.
    View in: PubMed
    Score: 0.004
  12. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin. Clin Pharmacol Ther. 1989 Apr; 45(4):340-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.